1. Safety in numbers: risankizumab for moderate‐to‐severe psoriasis. (1st March 2022) Authors: Mirali, S.; Fabusiwa, K.; Linos, E. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 394 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety in numbers: risankizumab for moderate‐to‐severe psoriasis. (20th February 2022) Authors: Mirali, S.; Fabusiwa, K.; Linos, E. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 394 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗